Bio-Rad Laboratories, Inc.

NYSE:BIO Lagerbericht

Marktkapitalisierung: US$8.2b

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Bio-Rad Laboratories Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Bio-Rad Laboratories wird ein jährliches Gewinn- und Umsatzwachstum von 47.6% bzw. 3.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 47.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 3.8% betragen.

Wichtige Informationen

32.8%

Wachstumsrate der Gewinne

32.6%

EPS-Wachstumsrate

Life Sciences Gewinnwachstum16.8%
Wachstumsrate der Einnahmen3.8%
Zukünftige Eigenkapitalrendite3.3%
Analystenabdeckung

Low

Zuletzt aktualisiert22 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Apr 18
Bio-Rad Laboratories (NYSE:BIO) Has A Pretty Healthy Balance Sheet

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Apr 14

At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Feb 07
At US$325, Is Bio-Rad Laboratories, Inc. (NYSE:BIO) Worth Looking At Closely?

Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Dec 17
Are Investors Undervaluing Bio-Rad Laboratories, Inc. (NYSE:BIO) By 43%?

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Nov 20
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Bio-Rad: Business Returns Aren't Economically Valuable, Sartorius Now A Hindrance

Oct 25

At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Oct 02
At US$358, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Aug 21
We Think Bio-Rad Laboratories (NYSE:BIO) Can Stay On Top Of Its Debt

Bio-Rad: A Cash Flow Returns On Investments Analysis

Aug 10

Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Jul 30
Are Bio-Rad Laboratories, Inc. (NYSE:BIO) Investors Paying Above The Intrinsic Value?

Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 04
Is It Too Late To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

May 23
Does Bio-Rad Laboratories (NYSE:BIO) Have A Healthy Balance Sheet?

A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

May 01
A Look At The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Apr 04
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs reports Q4 2022 results

Feb 16

Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Feb 10
Is Bio-Rad Laboratories (NYSE:BIO) A Risky Investment?

Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jan 20
Calculating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad: How Efficient Is Its Capital Management? A Deep Look, With Technicals

Jan 04

Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Dec 08
Why Bio-Rad Laboratories, Inc. (NYSE:BIO) Could Be Worth Watching

Bio-Rad Labs Non-GAAP EPS of $2.60 misses by $0.17, revenue of $680.8M misses by $1.9M

Oct 27

A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Oct 14
A Look At The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Will Bio-Rad And Qiagen Merge? I Can't See Any Logic To This Deal

Oct 12

Bio-Rad Laboratories hits 52-week low; down 40% YTD

Sep 19

Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Sep 02
Is Bio-Rad Laboratories (NYSE:BIO) Using Too Much Debt?

Bio-Rad Labs Non-GAAP EPS of $3.38 beats by $0.67, revenue of $691.1M beats by $26.5M

Jul 28

When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Jul 25
When Should You Buy Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Jul 04
Estimating The Fair Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

May 02
Bio-Rad Laboratories (NYSE:BIO) Has A Rock Solid Balance Sheet

Bio-Rad Offers Value If You Look

Mar 28

Bio-Rad Laboratories: Relentless Growth Supports A Bullish Outlook

Dec 25

Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Dec 10
Is Now The Time To Look At Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

Gewinn- und Umsatzwachstumsprognosen

NYSE:BIO - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20262,899326N/AN/A4
12/31/20252,794285N/AN/A5
12/31/20242,661294N/AN/A5
3/31/20242,605-322185347N/A
12/31/20232,671-637218375N/A
9/30/20232,720-159223374N/A
6/30/20232,769-428153287N/A
3/31/20232,779-191125242N/A
12/31/20222,802-3,62880194N/A
9/30/20222,805-6,021152286N/A
6/30/20222,871-1,930364505N/A
3/31/20222,896-91459606N/A
12/31/20212,9234,254536670N/A
9/30/20212,9806,659670783N/A
6/30/20212,8804,045590689N/A
3/31/20212,7014,098533626N/A
12/31/20202,5463,814480585N/A
9/30/20202,3803,521378450N/A
6/30/20202,2941,947323414N/A
3/31/20202,3291,579383478N/A
12/31/20192,3121,759368458N/A
9/30/20192,304377272403N/A
6/30/20192,289905251366N/A
3/31/20192,292574169288N/A
12/31/20182,289366156285N/A
9/30/20182,2941,277148250N/A
6/30/20182,2831,030116216N/A
3/31/20182,21276798201N/A
12/31/20172,160122N/A104N/A
9/30/20172,11017N/A130N/A
6/30/20172,08513N/A153N/A
3/31/20172,09726N/A168N/A
12/31/20162,06826N/A216N/A
9/30/20162,06798N/A157N/A
6/30/20162,02897N/A188N/A
3/31/20162,018108N/A149N/A
12/31/20152,019109N/A186N/A
9/30/20152,047103N/A190N/A
6/30/20152,10897N/A199N/A
3/31/20152,139100N/A237N/A
12/31/20142,17589N/A273N/A
9/30/20142,17980N/A304N/A
6/30/20142,15461N/A268N/A
3/31/20142,14264N/A211N/A
12/31/20132,13378N/A169N/A
9/30/20132,10491N/A194N/A
6/30/20132,098141N/A211N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: BIO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: BIO wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: BIO wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: BIODie Einnahmen des Unternehmens (3.3% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8% pro Jahr).

Hohe Wachstumseinnahmen: BIODie Einnahmen des Unternehmens (3.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: BIODie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (4.2%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y